US Patent Issued to DAIICHI SANKYO on Jan. 20 for "Treatment of HER3-mutated cancer by administration of anti-HER3 antibody-drug conjugate" (Japanese Inventors)

ALEXANDRIA, Va., Jan. 20 -- United States Patent no. 12,527,979, issued on Jan. 20, was assigned to DAIICHI SANKYO COMPANY Ltd. (Tokyo).

"Treatment of HER3-mutated cancer by administration of anti-HER3 antibody-drug conjugate" was invented by Kumiko Koyama (Tokyo), Yoshinobu Shiose (Tokyo) and Suguru Ueno (Tokyo).

According to the abstract* released by the U.S. Patent & Trademark Office: "A therapeutic agent for HER3-mutated cancer containing an anti-HER3 antibody-drug conjugate as an active ingredient and/or a method of treatment for cancer, the method including administering an anti-HER3 antibody-drug conjugate to a subject determined to have HER3-mutated cancer."

The patent was filed on Sept. 19, 2019, under Application No. 17/276,394...